As anti-GD2 mAb (ch14.18) in combination with IL-2, GM-CSF, and isotretinoin is approved as minimal residual disease (MRD) therapy for high-risk neuroblastoma patients, hu14.18-IL2 was evaluated in combination with GM-CSF and isotretinoin in recurrent or refractory neuroblastoma patients in a phase II study. The gene discussed is CSF2; the disease is neuroblastoma.